Nurix Therapeutics Appoints Drug Development Expert Roy D. Baynes, MB.Bch., M.Med., Ph.D., to Its Board of Directors

Core Insights - Nurix Therapeutics, Inc. has appointed Dr. Roy D. Baynes to its board of directors, bringing over 22 years of clinical leadership experience in hematology and oncology [1][2] - Dr. Baynes has been a trusted advisor to Nurix since 2023 and is expected to contribute significantly to the company's pipeline development in oncology and autoimmune indications [2] - Nurix focuses on targeted protein degradation medicines, aiming to improve treatment options for cancer and inflammatory diseases [3] Company Overview - Nurix Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of targeted protein degradation medicines [3] - The company's pipeline includes degraders of Bruton's tyrosine kinase (BTK) and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), with a focus on potentially first-in-class or best-in-class treatments [3] - Nurix has collaborations with major pharmaceutical companies such as Gilead Sciences, Sanofi, and Pfizer, retaining options for co-development and profit sharing in the U.S. for multiple drug candidates [3]